Prim. dr sci. med. Zoran Tomašević

Dr Zoran Tomašević je specijalista interne medicine sa 36 godina iskustva iz oblasti medikalne onkologije.

Radno mesto / Radno iskustvo

• 2022: Acibadem Bel Medic
• 2018 - 2022: Privatna internistička bolnica SirirusMedical – consultant
• 2017-2021: Privatna onkološka klinika IRVA – consultant
• 2015-2022: Dnevna bolnica za hemioterapiju Klinike za medikalnu onkologiju IORS - šef odseka
• 2000-2010: Pomoćnik direktora za zdravstvenu delatnost IORS;
• 1997-2000: Načelnik odeljenja kliničke laboratorije IORS
• Odeljenje hematološke onkologije Instituta za onkologiju i radiologiju Srbije (IORS); 1986-2000
• Odeljenje hematološke onkologije IORS; 1986-2000
  
  

Obrazovanje

• 1978 – 1983: Medicinski fakultet  Univerziteta u Beogradu
• 1988 – 1992: Specializacija interne medicine
• 1996: Magistarske studije iz onkologije na Medicinskom fakultetu Univerziteta u Beogradu; tema Hodgkin lymphoma
• 2009: Doktorska disertacija iz oblasti onkologije na Medicinskom fakultetu Univerziteta u Beogradu,; tema Hodgkin lymphoma
• 2017: Subspecijalizacija iz onkologije
• 2010: Naučni saradnik
  
  

Stručna usavršavanja

• ICH-GCP kurs
• Trening kurs Dobre klinicke praksa (Good Clinical Practice), ACRP, Beograd, 2009
• Glavni istrazivac i koistrazivac u nekoliko medjunarodnih klinickih studija
  
  

Stručne aktivnosti

• Nacionalni komitet za izradu vodiča kliničke prakse Ministarstva zdravlja Srbije; Rukovodilac radne grupe za izradu nacionalnih vodiča iz onkologije, 2002.
• Predsednik Udruženja Medikalnih Onkologa Srbije (UMOS), 2005-2010.
• Predavač po pozivu na velikom broju stručnih I naučnih skupova, u Srbiji i inostranstvu
  
  

Profesionalna članstva

• Lekarska komora Srbije, 1986.
• European Society of Oncology (ESO), 1988.
• Multinational Association of Supportive Care in Cancer (MASCC), 1997.
• European Society for Medical Oncology (ESMO), 1998.
• Društvo Srbije za borbu protiv raka, 2001.
• Central East European Oncology Group (CEEOG), 2002.
• American Society of Clinical Oncology (ASCO), 2003.
• Udruženje medikalnih onkologa Srbije (UMOS), 2005.
• Srpsko udruzenje za istrazivanje raka (SDIR), 2015
  
  

Posebna sfera interesovanja

• Solidni tumori: Karcinom dojke, ginekološki maligniteti, kolorektalni kancer, mekotkivni I koštani sarkomi, tumori pluća, tumori kože, tumori glave I vrata
• Hematološki maligniteti: Hodgkin i non-Hodgkin limfomi, multipli mijelom
• Suportivna terapija onkoloških bolesnika
• Klinička ispitivanja
  
  

Publikacije

MONOGRAPHS AND CHAPTERS IN MONOGRAPHS

• S. Jelić, N. Milanović, Z. Tomašević, V. Kovčin, L. Vuletić: High-doses epirubicin-cisplatin combination chemotherapy for advanced soft tissue sarcoma a preliminary report in epirubicin et ECCO 5, Gardner-Caldwell comun. Ltd. Medicclesfields 27, 1990
• V. Kovčin, S. Jelić, T. Petrović, N. Babović, Z. Tomašević, L. Vuletić. Ofloxacin Treatment for Localized Infections in Granulocytopenic Patients. in Jerzy Einhorn ed: Recent Advances in Chemotherapy, ASM Ed. Washington, 537-539, 1993.
• S. Jelić, I. Filipović-Lješković, Z. Tomašević, N. Manojlović: Serum lactoferrin in patients with breast and colon cancer and germ cell tumors of the testis. . In: Antypas G. ed: Balkan Congres of Oncology, Monduzzi Editore, Bolona, p. 575-579, 1996. 
• Ivanović S, Tomašević Z. et al. Chemotherapy of spinal tumors. Privredni pregled 2001. 
• Tomašević Z. et al. National Guidelines for malignant diseases (breast, lung, colorectal, ovary, testicular). Ministarstvo Zdravlja Republike Srbije, 2003.
  
  

INTERNATIONAL JURNALS IN EXTENSO (CURRENT CONTENTS)

• Jelić S, Vuletić L, Milanović N, Tomašević Z, Kovčin V: High-dose epirubicin-cisplatin chemotherapy for advanced soft tissue sarcoma. Tumori, 76,467-471, 1990
• Kovčin V, Jelić S, Babović N, Tomašević Z: A pilot study to assess the efficacy of salmon calcitonin in the relief of neuropathic pain caused by extra skeletal metastases. Support Care Cancer 1994, 2:71-73
• Jelić, L. Mitrović, V. Kovčin, Z. Nikolić-Tomašević, S. Radulović, Z. Tomašević, I.Popov: Modulation of cisplatin antitumor activity by short infusional high-dose cytosine arabinoside in advanced pretreated head and neck carcinoma: a phase II study. Journal of Chemotherapy, 8(4); 304-309, 1996
• S. Jelić, Z. Nikolić-Tomašević, V. Kovčin, N. Milanović, Z. Tomašević, V. Jovanović, M. Vlajić: A Two-Step Reevaluation of High-Dose Amsacrin for Advanced Carcinoma of the Upper aero digestive Tract: A pilot phase II study. Journal of Chemotherapy, 9 (5): 364-370, 1997.
• Tomašević Z. An emerging etiological agent of chemotherapy-induced febrile neutropenia: Acinetobacter as a cause of sporadic infections and a small nosocomial epidemic. Journal of Buon 4: 5-8, 1999
• Jelic S, Bosnjak S, Milanović N, Tomašević Z, Jovanović V. Aggresssive chemotherapy with G-CSF support for the so-called “Malignant Histiocytosis”. Journal of BUON 4: 269-273, 1999
• Popov I, Jelić S, Radulović S, Tomašević Z. Pilot study of enhancement of cisplatin activity by high dose cytarabine in advanced gastric and colorectal (G3/G4) cancer. Neoplasma, 1996; 43 (4), 221-224.
• S. Jelić, Z. Tomašević, M. Kreačić, V. Kovčin, D. Radosavljević, M. Vlajić: Etude pilote de la zorubicine a hautes doses dans les stades avances des sarcomes des tissus mous de l’adulte. Bull Cancer, 83;1002-1007, 1996.
• Jelić S, Milanović N, Tomašević Z, Matković S, Gavrilović D. Comparison of two non-anthracycline – containing regimens for elderly patients with diffuse large- cell non-hodgkin’s lymphoma; possible pitfalls in results reporting and interpretation. Neoplasma. 46(6), 1999.
• Tomasevic Z, Jelic S. Circulating immune complexes in advanced hodgkin’s disease: qualitative analysis and prognostic significance. Arch. Immunol Ther Exp 48(3): 195-200, 2000.
• Radosavljevic D, Jelic S , Tomasevic Z , Matkovic S , Stamatovic L , Nikolic- Tomasevic Z, Popov I. High-dose anthracyclines in the treatment of advanced primitive neuroectodermal tumors in adults--a single institution experience. Med Sci Monit. 6(3):512-8, 2000.
• Suvajdzic N, Stojanovic-Milenkovic R, Tomasevic Z , Cemerikic-Martinovic V , Mihaljevic B, Atkinson HD. ALK-negative T-cell anaplastic large cell lymphoma associated with systemic lupus erythematosus. Med Oncol 20(4):409-12, 2003. 
• Jelic S, Babovic N, Kreacic M, Matkovic S, Milanovic N, Gavrilovic D, Tomasevic Z Epirubicin 150 mg/m2-cisplatin versus epirubicin 180 mg/m2-cisplatin for advanced soft tissue sarcoma. Int J Clin Pharmacol Res. 19(4):129-38, 1999
• Ristic D, Tomasevic Z. Therapy of aggressive fibromatosis is still an open question: a series of patients treated at a single institution. Journal of BUON 10: 381-384, 2005. 
• Marinković M, Milošević D, Tomašević Z, Jelić S. The changes of serum immunoglobulins in patients treated by a combinatuion of anti-CD20 monoclonal antibody rituximab plus chlorambucil for low grade non-Hodgkin’s lymphoma. J BUON 7(4): 331-5,  002.
• Tomasevic Z, Radosevic-Jelic Lj, Jovanovic D, Milovanovic Z, Tomasevic ZM, Jelic S, Borojevic N. Brain metastases as late breast cancer relapse. Single institution experience and review of the literature. J BUON 14(2): 225-8, 2009. 
• Nikolic-Tomasevic Z, Jelic S, Cassidy J, Filipovic-Ljeskovic I, Tomasevic Z. Fluoropyrimidine therapy: hiperbilirubinemia as a consequence of hemolysis. Cancer Chemother Pharmacol. 56(6): 594-602, 2005 
• Jelic S, Mitrovic L, Radosavljevic D, Elezar E, Babovic N, Kovcin V, Tomasevic Z, Kovacevic S, Gavrilovic D, Rdulovic S. Survival advantage for carboplatin substituting cisplatin in combination with vindesine and mitomycin C for stage IIIB and IV squamous cell bronchogenic carcinoma: a randomized phase III study. Lung cancer 34(1): 1-13, 2001.
• Tomasevic ZI, Rakocevic Z, Tomasevic ZM, Milovanovic Z, Inic M, Kolarevic D,Lukic V, Kovac Z. Incidence of brain metastases in early stage HER2 3+ breast cancer patients; Is there a role for brain CT in asymptomatic patients? Journal of BUON 17: 249-253, 2012 
• Todorovic V, Aapro M, Pavlidis N, Arsovski O, Belkacemi Y, Babovic N, Bidard FC, Bourhafour M, Beslija S, Boussen H, Cetnikovic B, Ceric T, Cicmil N, Crnogorac N, Cuedari E, De Laurentis M, Dragovich T, Durutovic I, Dzamic Z, Dzodic R, Eri Z, Geara F, Khalil A, Kerrou K, Knezevic Usaj S, Kovcin V, Koroveshi D, Kristo Pema A, Kuten A, Lakicevic J, Lukovac N, Markovic I, Markovic M, Mijalkovic N, Miladinova D, Milasevic N, Mustachi G, Ognjenovic D, Pantelic A, Popovic L, Radosavljevic D, Radosevic N, Radulovic S, Ristevski M, Rosic I, Secen N, Sorat M, Stamatovic L, Stefanovski P, Stojkovski I, Tesanovic D, Tomasevic Z, Tomasevic Z, Tsoutsou P, Turkan S, Vasev N, Vasovic S, Vicko F, Vrbanec D, Vukmirovic F, Vrdoljak E, Zaric B, Zambrovski JJ, Cavalli F, Gligorov. AROME-ESO Oncology Consensus Conference: access to cancer care innovations in countries with limited resources. Association of Radiotherapy and Oncology of the Mediterranean Area (AROME-Paris) and European School of Oncology (ESO - Milan). Journal of BUON. 24(5): 2180-2197, 2019.